Our previous observation that canakinumab, a monoclonal antibody targeting IL-1β and reducing both IL-6 and CRP, did not reduce blood pressure or the development of hypertension in a population of CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial [43] makes reverse causality less likely. Here, IL1B is linked to hypertensive disorder.